Javara Secures Significant Strategic Growth Investment from General Atlantic

Javara Secures Strategic Series B Investment from General Atlantic to Expand Integrated Research Model

WINSTON-SALEM, N.C. – Javara, a leading Integrated Research Organization (IRO) and pioneer of Clinical Research as a Care Option (CRAACO), announced it has secured a significant Series B strategic growth investment from global growth equity firm General Atlantic.

Founded in 2018 by Jennifer Byrne (CEO), Amanda Wright (CDO), and Linda McCarty (General Counsel and Privacy Officer), Javara was built with a mission to revolutionize clinical research by accelerating access for patients, biopharma companies, and healthcare organizations alike.

The new funding will be used to drive geographic expansion and technological advancement, further integrating clinical research into the healthcare ecosystem and providing more patients with access to clinical trials through their trusted physicians.

As part of the investment, Brett Zbar, M.D., Managing Director and Global Head of Life Sciences at General Atlantic, and Joe von Rickenbach, Senior Advisor at General Atlantic and Co-Founder, Former Chairman and CEO of PAREXEL International Corporation, will join Javara’s Board of Directors.

Transforming Clinical Research Delivery

Javara is reimagining the delivery of clinical research by bridging the gap between clinical trials and routine care. Unlike traditional standalone research sites that operate independently from physicians and patient health records, Javara partners closely with healthcare organizations to embed research infrastructure and staff within care settings.

This model produces higher patient diversity, stronger retention, and improved data quality — while reducing barriers to participation. Javara currently partners with an extensive network of leading pharmaceutical, biotech, and contract research organizations.

“We founded Javara with a vision to transform clinical research delivery, creating a business and technology framework whereby clinical trials are on the menu of care options for all patients within the entire healthcare system,” said Jennifer Byrne, CEO of Javara. “Our goal is to drive value across the industry while ensuring that all patients have access to the care they deserve. Partnering with General Atlantic allows us to expand access, increase diversity, and address long-standing barriers to participation in research.”

Improving Access, Retention, and Trial Outcomes

The traditional clinical trial system is riddled with inefficiencies: on average, standalone sites enroll only 28% of targeted patients, 20% fail to enroll a single patient, and nearly 80% of all trials fail to finish on time — resulting in delays and losses for sponsors.

By bringing clinical trials directly into the point-of-care environment, Javara shortens recruitment timelines, improves retention, and breaks down socioeconomic barriers that have historically limited access for underrepresented populations.

“Our partnership with Javara is grounded in General Atlantic’s conviction that the integrated research model offers a compelling alternative to traditional site-based clinical investigation,” said Dr. Brett Zbar, Managing Director at General Atlantic. “We believe this model can increase the efficiency and quality of clinical trials and, ultimately, improve patient outcomes.”

Joe von Rickenbach, Senior Advisor at General Atlantic, added: “Javara has developed a creative solution to longstanding hurdles in the clinical trial ecosystem, offering speed, scale, diversity, and quality advantages at a critical time when trials are becoming more complex and costly.”

Advisory and Legal Partners

Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, LLP, Morgan Lewis & Bockius LLP, and HCiT Capital Advisors LLC advised Javara on the Series B funding round.

About Javara

Javara partners with large healthcare organizations to deliver clinical trial access at the point of care through integrated research staff and infrastructure. By embedding research capabilities within health systems, Javara connects broad, diverse patient populations with relevant trials — improving enrollment, retention, and data quality.

As pioneers of Clinical Research as a Care Option (CRAACO), Javara’s centralized resources and standardized operations enable faster study start-up and high-quality outcomes, transforming healthcare and changing lives by connecting the right patients to the right trials at the right time.

Learn more at JavaraResearch.com.

About General Atlantic

General Atlantic is a leading global growth equity firm with more than four decades of experience supporting over 445 growth companies. Founded in 1980, the firm partners with visionary entrepreneurs to scale innovative businesses through long-term capital, deep sector expertise, and strategic support.

General Atlantic currently manages over $84 billion in assets (as of December 31, 2021) and maintains offices in New York, London, São Paulo, Mumbai, Singapore, and other major global markets.

For more information, visit www.generalatlantic.com.

Full press release available here.

‍